Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet (PODD – Research Report) today. The company’s shares opened today at $181.87.
Steed covers the Healthcare sector, focusing on stocks such as Stryker, Shockwave Medical, and Abbott Laboratories. According to TipRanks, Steed has an average return of 6.9% and a 64.19% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insulet with a $237.92 average price target, which is a 30.82% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $230.00 price target.
The company has a one-year high of $331.65 and a one-year low of $125.82. Currently, Insulet has an average volume of 880.4K.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PODD in relation to earlier this year. Most recently, in February 2024, Shacey Petrovic, a Director at PODD sold 11,609.00 shares for a total of $1,891,338.28.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet (PODD) Company Description:
Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
